Logo image of VRDN

VIRIDIAN THERAPEUTICS INC (VRDN) Stock Fundamental Analysis

NASDAQ:VRDN - Nasdaq - US92790C1045 - Common Stock - Currency: USD

16.27  -0.35 (-2.11%)

After market: 16.5 +0.23 (+1.41%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to VRDN. VRDN was compared to 572 industry peers in the Biotechnology industry. The financial health of VRDN is average, but there are quite some concerns on its profitability. VRDN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VRDN had negative earnings in the past year.
In the past year VRDN has reported a negative cash flow from operations.
In the past 5 years VRDN always reported negative net income.
In the past 5 years VRDN always reported negative operating cash flow.
VRDN Yearly Net Income VS EBIT VS OCF VS FCFVRDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M -250M

1.2 Ratios

With a decent Return On Assets value of -33.31%, VRDN is doing good in the industry, outperforming 63.77% of the companies in the same industry.
VRDN has a better Return On Equity (-36.34%) than 74.07% of its industry peers.
Industry RankSector Rank
ROA -33.31%
ROE -36.34%
ROIC N/A
ROA(3y)-39.1%
ROA(5y)-67.96%
ROE(3y)-42.99%
ROE(5y)-97.25%
ROIC(3y)N/A
ROIC(5y)N/A
VRDN Yearly ROA, ROE, ROICVRDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

VRDN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRDN Yearly Profit, Operating, Gross MarginsVRDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K

More info and screens

5

2. Health

2.1 Basic Checks

VRDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
VRDN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for VRDN has been increased compared to 5 years ago.
Compared to 1 year ago, VRDN has a worse debt to assets ratio.
VRDN Yearly Shares OutstandingVRDN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
VRDN Yearly Total Debt VS Total AssetsVRDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 10.26 indicates that VRDN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 10.26, VRDN belongs to the top of the industry, outperforming 87.39% of the companies in the same industry.
A Debt/Equity ratio of 0.03 indicates that VRDN is not too dependend on debt financing.
VRDN has a worse Debt to Equity ratio (0.03) than 60.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 10.26
ROIC/WACCN/A
WACC9.44%
VRDN Yearly LT Debt VS Equity VS FCFVRDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 18.55 indicates that VRDN has no problem at all paying its short term obligations.
With an excellent Current ratio value of 18.55, VRDN belongs to the best of the industry, outperforming 93.61% of the companies in the same industry.
A Quick Ratio of 18.55 indicates that VRDN has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 18.55, VRDN belongs to the best of the industry, outperforming 93.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 18.55
Quick Ratio 18.55
VRDN Yearly Current Assets VS Current LiabilitesVRDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.49% over the past year.
The Revenue for VRDN has decreased by -13.71% in the past year. This is quite bad
VRDN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -48.16% yearly.
EPS 1Y (TTM)15.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.5%
Revenue 1Y (TTM)-13.71%
Revenue growth 3Y-33.13%
Revenue growth 5Y-48.16%
Sales Q2Q%19.44%

3.2 Future

Based on estimates for the next years, VRDN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.45% on average per year.
The Revenue is expected to grow by 346.51% on average over the next years. This is a very strong growth
EPS Next Y23.58%
EPS Next 2Y9.08%
EPS Next 3Y6.93%
EPS Next 5Y15.45%
Revenue Next Year-15.41%
Revenue Next 2Y-21.66%
Revenue Next 3Y370.16%
Revenue Next 5Y346.51%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VRDN Yearly Revenue VS EstimatesVRDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
VRDN Yearly EPS VS EstimatesVRDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VRDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VRDN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRDN Price Earnings VS Forward Price EarningsVRDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRDN Per share dataVRDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.08%
EPS Next 3Y6.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VRDN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRIDIAN THERAPEUTICS INC

NASDAQ:VRDN (2/21/2025, 8:00:01 PM)

After market: 16.5 +0.23 (+1.41%)

16.27

-0.35 (-2.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)05-06 2025-05-06/amc
Inst Owners115.67%
Inst Owner Change-81.92%
Ins Owners0.04%
Ins Owner Change1.15%
Market Cap1.29B
Analysts85.22
Price Target41.25 (153.53%)
Short Float %14.25%
Short Ratio7.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.57%
Min EPS beat(2)-12.54%
Max EPS beat(2)-6.6%
EPS beat(4)1
Avg EPS beat(4)-5.31%
Min EPS beat(4)-31.95%
Max EPS beat(4)29.83%
EPS beat(8)3
Avg EPS beat(8)-13.6%
EPS beat(12)5
Avg EPS beat(12)-11.68%
EPS beat(16)6
Avg EPS beat(16)-74.52%
Revenue beat(2)1
Avg Revenue beat(2)33.07%
Min Revenue beat(2)-18.06%
Max Revenue beat(2)84.21%
Revenue beat(4)1
Avg Revenue beat(4)2.39%
Min Revenue beat(4)-55.77%
Max Revenue beat(4)84.21%
Revenue beat(8)1
Avg Revenue beat(8)-23.32%
Revenue beat(12)3
Avg Revenue beat(12)3.9%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.46%
EPS NQ rev (1m)-0.13%
EPS NQ rev (3m)-0.01%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)-2.94%
Revenue NQ rev (1m)8.33%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4267.37
P/FCF N/A
P/OCF N/A
P/B 1.82
P/tB 1.82
EV/EBITDA N/A
EPS(TTM)-4.31
EYN/A
EPS(NY)-4.31
Fwd EYN/A
FCF(TTM)-2.49
FCFYN/A
OCF(TTM)-2.49
OCFYN/A
SpS0
BVpS8.93
TBVpS8.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.31%
ROE -36.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.1%
ROA(5y)-67.96%
ROE(3y)-42.99%
ROE(5y)-97.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.21%
Cap/Sales 147.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.55
Quick Ratio 18.55
Altman-Z 10.26
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)254.35%
Cap/Depr(5y)161.46%
Cap/Sales(3y)114.22%
Cap/Sales(5y)69.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.5%
EPS Next Y23.58%
EPS Next 2Y9.08%
EPS Next 3Y6.93%
EPS Next 5Y15.45%
Revenue 1Y (TTM)-13.71%
Revenue growth 3Y-33.13%
Revenue growth 5Y-48.16%
Sales Q2Q%19.44%
Revenue Next Year-15.41%
Revenue Next 2Y-21.66%
Revenue Next 3Y370.16%
Revenue Next 5Y346.51%
EBIT growth 1Y-21.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.88%
EBIT Next 3Y-11.68%
EBIT Next 5Y43.08%
FCF growth 1Y-156.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-158.07%
OCF growth 3YN/A
OCF growth 5YN/A